Objective: This retrospective study was designed to detect occult micrometastases in the lymph nodes with the use of monoclonal anti-cytokeratin reagent, which is specific for epithelial cells but not for lymphocytes or plasmacytes, as well as to assess the relationship between the presence of occult micrometastases in the lymph nodes and an early relapse in patients with stage I non-small-cell lung cancer. 
tasis to the regional lymph nodes, recurrent disease develops within the early interval after operation, and the 5-year-survivals are estimated to be about 64% to 75%. 1 '2 This suggests that the pathologic stage as determined by conventional hematoxylineosin (HE) staining may be underestimated and thus the occult metastatic stage may remain undetected. An accurate assessment of the presence and absence of tumor cells in the regional lymph nodes is therefore critical for making an accurate prognosis for patients with lung cancer. [3] [4] [5] The development of sensitive immunohistochemical techniques and specific monoclonal antibodies, such as keratin, cytokeratin (CK), and BerEp4, have increased our capacity to detect small clusters of tumor cells in breast and lung cancer or even single tumor cells in the lymph nodes that appear to be negative on examination of HE-stained slides. 6-9 We focused our attention on the epithelial marker, CK, which might be effective for detecting micrometas- This retrospective study was thus designed both to detect occult micrometastases in the lymph nodes by means of a monoclonal anti-CK reagent as well as to distinguish between the presence of occult micrometastases in the lymph nodes and an early relapse in patients with node-negative stage I NSCLC.
Patients, methods, and follow-up
tn a series of 95 consecutive patients operated on for NSCLC at the Department of Surgery II, Faculty of Medicine, Kyushu University, between January 1991 and December 1992, we studied 44 patients with stage I disease (23:T1 NO M0; 21:T2 NO M0) who underwent a lobectomy combined with a formal mediastinal and hilar node dissection. The stage of the disease was based on the TNM classification of the Union Internationale Contre Cancer (UICC). 13 The patients consisted of 24 men and 20 women. The median age of the patients was 66 years, with a range from 25 to 78 years. Twenty-nine patients had adenocarcinoma, 13 had squamous cell carcinoma, one had large-cell carcinoma, and one had mucoepidermoid carcinoma. The median number of lymph nodes available for examination from each patient was 23 with a range from 8 to 45.
After the operation, the patients were reexamined every month for 1 year, once every 2 months for an additional 2 years, once every 3 months for an additional 3 years, and thereafter at 6-month intervals. The evaluations included a physical examination and chest roentgenograms at each visit and computed tomography and a bone scan every year. The median follow-up duration of the patients was 48 months with a range from 7 to 66 months.
To compare with N factor restaged by CK, we used, as a control group, patients with completely resected pathologic T1 or T2 N1 M0 (n = 78) and T1 or T2 N2 M0 (n = 96) NSCLC determined by conventional HE staining at our department from 1975 to 1995. The characteristics of the patients according to the T factor of stage I and of the control subjects are shown in Table I .
Immunostaining procedure of CK. Paraffin-embedded tissue sections 5 /xm thick were floated onto 0.01% lysine-coated slides. We used the primary monoclonal antibody to CKs (clone: CAM-5.2, Becton Dickinson Immunocytometry Systems, San Jose, Calif.) and an indirect staining technique and the streptavidin-biotin-peroxidase complex method. After blocking endogenous peroxidase with hydrogen peroxide, all deparaffinized sections were incubated with 0.1% type II trypsin for 20 minutes at 37°C to reveal the antigenic site. Possible background staining was also removed by applying normal rabbit serum, diluted 1:10, for 20 minutes at room temperature. We applied mouse CK monoclonal antibody overnight at 4 ° C; then biotinylated secondary antibody and streptavidin with mouseradish peroxidase (Nichirei Corp., Tokyo, Japan) were applied for 15 and 10 minutes, respectively. Next, all slides were counterstained with methyl green. To directly compare the effectiveness of immunohistochemical analyses with the conventional HE method, we studied two additional sections consecutive to those displaying CK-positive cells. One section was stained by routine HE staining, and the other was immunostained with CK. The presence of CK-positive cells within the body of the lymph nodes was considered to represent metastatic tumor cells even if only one single CK-positive cell was detected.
All slides were examined by two independent observers in a double blind fashion.
Statistical analysis. Survival was calculated from the date of operation until death or the date of the last follow-up (censored). The duration of the disease-free survival was measured from the date of operation until the first evidence of recurrence from primary NSCLC or the last date of follow-up for patients who remained alive and disease free (censored); six patients who died of a cause other than primary NSCLC without any evidence of disease were censored at death. The disease-free interval and survival were analyzed according to the Kaplan-Meier method and differences in their distribution were evaluated by means of the log-rank test. l< 15 Ap value less than 0.05 was defined as being statistically significant. Cox proportional hazards models were applied for multivariate analysis. 16 Data were analyzed with the use of Abacus Concepts, Survival Tools for StatView (Abacus Concepts, Inc., Berkeley, Calif.).
Results
Lymph node micrometastases detected by CK. First, we tried to confirm a reactivity of the anti-CK monoclonal antibody in the primary lesion of 44 cases in this study. All cases showed a strong positivity with CK immunohistochemistry (not shown). We examined a total of 973 lymph nodes from 44 patients with conventional stage I disease. We thus identified CK-positive cells in 25 (5.6%) of the 450 lymph nodes from patients with T1 NO M0 disease and in 66 (12.6%) of the 523 lymph nodes from patients with T2 NO M0 disease in whom metastases had not been detected by a routine examination of HE-stained slides. In positive lymph nodes, either single metastatic tumor cells or small clusters of such cells were usually present in the subcapsular or medullary sinuses and less frequently in the afferent lymphatics or in the true lymphoid areas of the node (Fig. 1, A and B) .
Among 23 patients with T1 N0 M0 disease, CKpositive cells in the lymph nodes of the hilar and Fig. 2, A and B) . Relationship between recurrence and micrometastasis. Follow-up data were available for at least 3 years on these patients after the operation. Among 23 patients with T1 NO M0 disease, four patients had recurrence in this period; the sites of recurrence included the bone in one, the contralateral lung in one, the brain in one, and the mediastinat lymph nodes in one. Of the four patients with recurrence, three had N1 or N2 disease with micrometastasis in the nodes that were undetectable in the routine examination of HE staining, but were visible with the use of immunohistochemical techniques. Among 21 patients with T2 NO M0 disease, nine patients had recurrence in this period; the sites of recurrence were the mediastinal lymph nodes in one, the ipsilateral lung in two, the contralateral lung in one, the bone in three, the brain in three, the liver in two, and the skin in one. In the nine patients with recurrence, two had N1 disease and seven had N2 disease with micrometastasis in the lymph nodes. Fig. 3 shows the disease-free survival by N factor restaged by CK. In patients with NO disease restaged by CK (CK-N0), 3-year disease-free survival was 92.3%. In patients with N1 disease restaged by CK (CK-N1), the 1-and 3-year disease-free survivals were 94.4% and 77.8%, respectively. In patients with N2 disease restaged by CK (CK-N2), the 1-and 3-year disease-free survivals were 66.7% and 33.3%, respectively. The duration of disease-free survival was significantly shorter in patients with CK-N2 disease than in those with CK-N0 and CK-N1 disease (p = 0.004 and p = 0.008).
The overall 5-year survival was 64.4% in this study. Fig. 4 shows the survival by N factor restaged by CK. The 5-year survivals were 83.0% for patients with CK-N1 disease and 27.8% for patients with CK-N2 disease. The 5-year survival was 90.9% for patients with CK-N0 disease, and the difference between CK-N0 and CK-N2 disease was significant (/9 = 0.036).
We next compared the patients having CK-N1 disease with the patients having completely resected pathologic T1 or T2 N1 M0 disease (n = 78), and we compared the patients having CK-N2 disease with those having completely resected pathologic T1 or T2 N2 M0 disease (n = 96). Fig. 5 , A shows the survival both of the patients with pathologic N1 disease and of those with CK-N1 disease. Survival was significantly shorter in the patients with pathologic N1 disease than in the patients with CK-N1 disease (p < 0.001). Fig. 5 , B shows the survival of patients with pathologic N2 disease and CK-N2 disease, and the difference between the two modalities was not significant. Table II demonstrates univariable risk ratios, 95% confidence intervals, and p values on early tumor relapse rates. It was demonstrated that only micrometastases in the mediastinal lymph nodes were prognostic factors in multivariable models (hazards ratio = 8.508; 95% confidence intervals = 1.019, 71.039; p value = 0.048).
Discussion
Up to now, the pathologic staging of cancer has been primarily based on an examination of the HE-stained nodes. Single tumor cells or small clusters of tumor cells nestled among the lymphocytes and/or sinus histiocytes can be easily overlooked, thus leading to a false-negative assessment. Occult micrometastases in the lymph nodes have also been identified by other investigators using immunohistochemical techniques in breast and lung cancer 6-9 and by others using molecular biologic techniques in colorectal and lung cancer. 17-19 Hayashi and associates 18 reported micrometastases in the lymph nodes of the patients with eolorectal cancer using the mutant allele-specific amplification method, and this method was also useful for detecting K-ras mutations. 17 Betz and coworkers, 19 using the reverse transcriptase-polymerase chain reaction method targeting pulmonary surfactant apoprotein, reported detecting micrometastases in the lymph nodes of patients with NSCLC.
This study emphasized the value of immunohistochemistry in detecting micrometastases in the lymph nodes and assessed the relationship between presence of micrometastases in the lymph nodes and an early relapse in patients with node-negative stage I NSCLC.
All types of epithelial tissue, both normal and malignant, contain CKs, which form the intermediate filament cytoskeleton within the epithelial cell. This family of human CKs consists of 19 different polypeptides, which have been numbered 1 through 19 by Moll and associates. I° We used CAM-5.2, which recognizes CKs 8 and 18, as the monoclonal anti-CK reagent in this study. 12 CKs 8 and 18 were detected in the tumor cells of both adenocarcinoma and squamous cell carcinoma of the lung. 11 Therefore this immunohistochemical method can be effectively applied to almost all cases of NSCLC. Anti-CK reagents have some advantages and disadvantages. The anti-CK reagent is not specific for lung cancer cells, and a positive reaction was also seen with nontumor cells in the lymph nodes. In addition, Traweek, Liu, and Battifora 2° reported that variable levels of keratin 8 and 18 gene expression were detected by reverse transcriptase-polymerase chain reaction targeting to CK in normal lymph nodes. Therefore it remains possible that the 21 However, in addition to comparing the morphologic and staining similarities of primary lesions, the standard cytologic criteria of cell and nuclear size, nucleolation, and the nucleus-cytoplasmic ratio allowed us to easily distinguish CK-positive tumor cells from nontumor cells while ruling out a false-positive finding of occult metastases in the lymph nodes with this immunohistochemical method. Even if any doubt remains as to whether a single tumor cell or small clusters of tumor cells in the lymph nodes by immunohistochemical methods reflect overt clinical metastasis, their presence might indicate a poor prognosis. According to many reports, the 5-year survivals in patients with pathologic N1 disease and N2 disease were 39% to 43% and 14% to 30%, respectively, 2' 3, 23~26 and our results correspond with these reports. We compared the patients having CK-N1 disease with the patients having completely resected pathologic T1 or T2 N1 M0 disease, and we compared the patients having CK-N2 disease with those having completely resected pathologic T1 or T2 N2 M0 disease. As a result, tumor cells in the lymph nodes by immunohistochemical methods reflect overt pathologic metastases in the patients with CK-N2 disease, but not in those with CK-N1 disease.
However, regarding the sites of recurrence in this study, distant metastases were more frequent than local recurrence, and the pattern of metastasis was more often hematogenous than lymphogenous. Martini and associates 26 reported on 114 patients with recurrence in 214 patients with stage II lung cancer. Ninety patients (79%) had distant metastases. As their report indicated, the nodal involvement did not necessarily reflect lymphogenous metastases, but might be an indicator of hematogenous spread. Of 31 patients with CK-detected lymph node micrometastases, 19 patients did not have a recurrence. We can be fairly certain that all patients underwent complete resections in our study. However, systemic micrometastatic spread might have occurred in some patients with CK-positive lymph nodes disease, especially CK-N2 disease. Pantel and associates 27 reported the CK immunocytologic detection of bone marrow micrometastasis in patients with NSCLC. The immunohistochemical methods with anti-CK reagent may thus be useful for performing an accurate assessment of the clinical stage.
Passlick and coworkers 9 previously demonstrated that patients with lymph node micrometastases showed a significantly shorter disease-free survival duration than patients with negative nodes, and their findings were confirmed by our present study. In addition, we indicated the relationship between early recurrence and micrometastases in the mediastinal lymph nodes of patients with stage I NSCLC for the first time. We may thus believe that stage I NSCLC with CK-positive mediastinal lymph nodes represents occult advanced disease with potential indications for adjuvant therapy.
